Skip to main content

$0.125 (0.00%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
19 May 2025 at 5:51pm
Register to track EMD and receive email alerts.

Ethics approval received for EMD-RX5 Phase 1 Study

StockBot

416,823 posts

EMD released this announcement to the ASX on 3 March 2022, 13:41. The announcement is marked as price sensitive, and is 3 page(s) in length and 135.53kb in size.

You can view all announcements from EMD and see how they appear on a price chart on the announcements page.

At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).

Other Recent Announcements from EMD
Trading Halt 29 June 2023, 9:33
Emyria Receives Ethics Approval for MDMA-assisted Therapy 8 June 2023, 9:10
Section 708A(5)(e) Notice 10 May 2023, 18:37
Ethics approval received for EMD-RX5 Phase 1 Study 3 March 2022, 13:41
Emyria to present at Hidden Gems Webinar March 4th 2 March 2022, 10:38
Half Yearly Report and Accounts 28 February 2022, 18:27
Emyria grows its novel MDMA-analogue library 22 February 2022, 9:53
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track EMD and receive email alerts.